---
schema_version: "secwatch.filing_event.v1"
accession: "0001022079-25-000219"
form_type: "8-K"
ticker: "DGX"
cik: "0001022079"
company_name: "QUEST DIAGNOSTICS INC"
filed_at: "2025-10-21T23:59:59+00:00"
generated_at: "2026-05-17T02:56:00.110442+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Quest Diagnostics Q3 revenue $2.82B (+13.1%), raises FY2025 adjusted EPS guidance to $9.76–$9.84

## Summary
- Q3 reported diluted EPS $2.16 (+8.5%); adjusted diluted EPS $2.60 (+13.0%) vs $2.30 prior year.
- Revenue up 13.1% to $2.82B with 6.8% organic growth; diagnostic info services revenue $2.76B.
- FY2025 adjusted EPS guidance raised to $9.76–$9.84 from $9.63–$9.83; revenue guidance raised to $10.96B–$11.00B.
- Year-to-date cash from operations $1.42B, up 63.1%; Co-Lab Solutions annual revenue run-rate ~$1B expected next year.
- Announced lab services JV with Corewell Health; acquired dialysis testing assets from Fresenius Medical Care.

## SEC filing metadata
- accession: 0001022079-25-000219
- form_type: 8-K
- ticker: DGX
- cik: 0001022079
- company_name: QUEST DIAGNOSTICS INC
- filed_at: 2025-10-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022079/000102207925000219/0001022079-25-000219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022079/000102207925000219/dgx-20251021.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001022079-25-000219
- JSON: https://secwatch.observer/filing/0001022079-25-000219.json
- Plain text: https://secwatch.observer/filing/0001022079-25-000219.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.